NVS NOVARTIS AG-SPONSORED ADR
2026Q2 · CUSIP 66987V109 · Sector: Healthcare & Biotech
Funds are exiting, but the price is holding
1,573 funds held NVS at the end of 2026Q2, down 11 from the quarter before. Buying has faded, though the price is holding up. On the business itself, revenue over the last 12 months was $54.5B(YoY +8.4%), the P/E is 22.6x. NVS has had 26 buying rushes in its history, and the price moved +3.6% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.
How many funds owned it, quarter by quarter
Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.
What happened after each past buying rush 26 times in its history
| Quarter of the rush | How unusual then | Price, next 3 months | Price, next 6 months |
|---|---|---|---|
| 2026Q1 | Top 5% | +4.3% | — |
| 2025Q4 | Top 5% | -4.9% | -5.4% |
| 2025Q2 | Top 10% | +5.6% | +5.8% |
| 2025Q1 | Top 20% | +10.3% | +12.9% |
| 2024Q4 | Top 20% | +9.0% | +7.8% |
| 2024Q2 | Top 5% | -0.2% | -9.9% |
| 2023Q4 | Top 10% | +0.4% | +6.2% |
| 2023Q3 | Top 10% | +11.4% | +9.2% |
These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.
Show all the numbers (large funds, value held, options…) ▾ Collapse ▴
These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.
8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.
Fundamentals
As of 2025-12-31 · SEC filings (XBRL)
Email me the next update
2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.